These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12641538)

  • 1. Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial.
    Vermeulen EG; Rauwerda JA; van den Berg M; de Jong SC; Schalkwijk C; Twisk JW; Stehouwer CD
    Eur J Clin Invest; 2003 Mar; 33(3):209-15. PubMed ID: 12641538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial.
    Vermeulen EG; Stehouwer CD; Valk J; van der Knaap M; van den Berg M; Twisk JW; Prevoo W; Rauwerda JA
    Eur J Clin Invest; 2004 Apr; 34(4):256-61. PubMed ID: 15086356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect of folic acid on markers of endothelial dysfunction or inflammation in patients with type 2 diabetes mellitus and mild hyperhomocysteinaemia.
    Spoelstra-de MA; Brouwer CB; Terheggen F; Bollen JM; Stehouwer CD; Smulders YM
    Neth J Med; 2004; 62(7):246-53. PubMed ID: 15554600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Combined Treatment With Folic Acid, Vitamin B
    Christen WG; Cook NR; Van Denburgh M; Zaharris E; Albert CM; Manson JE
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.
    Vermeulen EG; Stehouwer CD; Twisk JW; van den Berg M; de Jong SC; Mackaay AJ; van Campen CM; Visser FC; Jakobs CA; Bulterjis EJ; Rauwerda JA
    Lancet; 2000 Feb; 355(9203):517-22. PubMed ID: 10683000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial.
    Dusitanond P; Eikelboom JW; Hankey GJ; Thom J; Gilmore G; Loh K; Yi Q; Klijn CJ; Langton P; van Bockxmeer FM; Baker R; Jamrozik K
    Stroke; 2005 Jan; 36(1):144-6. PubMed ID: 15569860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease.
    Stott DJ; MacIntosh G; Lowe GD; Rumley A; McMahon AD; Langhorne P; Tait RC; O'Reilly DS; Spilg EG; MacDonald JB; MacFarlane PW; Westendorp RG
    Am J Clin Nutr; 2005 Dec; 82(6):1320-6. PubMed ID: 16332666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of folic acid and vitamins B6 and B12 on microcirculatory vasoreactivity in patients with hyperhomocysteinemia.
    Abularrage CJ; Sidawy AN; White PW; Aidinian G; Dezee KJ; Weiswasser JM; Arora S
    Vasc Endovascular Surg; 2007; 41(4):339-45. PubMed ID: 17704338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia.
    van den Berg M; Franken DG; Boers GH; Blom HJ; Jakobs C; Stehouwer CD; Rauwerda JA
    J Vasc Surg; 1994 Dec; 20(6):933-40. PubMed ID: 7990188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation.
    Manrique J; Diáz A; Gavira JJ; Hernández A; Pujante D; Errasti P
    Transplant Proc; 2005 Nov; 37(9):3782-4. PubMed ID: 16386537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease.
    Schernthaner GH; Plank C; Minar E; Bieglmayer C; Koppensteiner R; Schernthaner G
    Eur J Clin Invest; 2006 May; 36(5):333-9. PubMed ID: 16634837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study.
    de Jong SC; Stehouwer CD; van den Berg M; Geurts TW; Bouter LM; Rauwerda JA
    J Intern Med; 1999 Jul; 246(1):87-96. PubMed ID: 10447230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
    Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
    JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
    Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M
    JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Homocysteine--a risk factor for atherosclerosis].
    Debreceni L
    Orv Hetil; 2001 Jul; 142(27):1439-44. PubMed ID: 11481906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Homocysteine and diabetic macroangiopathy].
    Araki A
    Nihon Rinsho; 2006 Nov; 64(11):2153-8. PubMed ID: 17087311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
    Bleie Ø; Semb AG; Grundt H; Nordrehaug JE; Vollset SE; Ueland PM; Nilsen DW; Bakken AM; Refsum H; Nygård OK
    J Intern Med; 2007 Aug; 262(2):244-53. PubMed ID: 17645592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.